Cognitive and anatomic contributions of metabolic decline in Alzheimer disease and cerebrovascular disease

被引:34
|
作者
Kuczynski, Beth [1 ,2 ,3 ]
Reed, Bruce [4 ]
Mungas, Dan [4 ]
Weiner, Michael [5 ]
Chui, Helena C. [6 ]
Jagust, William [1 ,2 ,3 ]
机构
[1] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA
[2] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA
[3] Univ Calif Davis, Alzheimers Dis Res Ctr, Davis, CA 95616 USA
[4] No California Vet Affairs Hlth Care Syst, Sacramento, CA USA
[5] Univ Calif San Francisco, Med Ctr, Dept Vet Affairs, San Francisco, CA 94143 USA
[6] Univ So Calif, Sch Med, Dept Neurol, Los Angeles, CA 90033 USA
关键词
D O I
10.1001/archneur.65.5.650
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Alzheimer disease and cerebrovascular disease affect elderly persons through alterations in brain structure and metabolism that produce cognitive decline. Understanding how each disease contributes to dementia is essential from both a pathophysiologic and diagnostic perspective. Objective: To elucidate how baseline cognitive function (episodic memory and executive function) and brain anatomy (white matter hyperintensities and hippocampal volume) are associated with baseline (positron emission tomography-1 [PET1]) and longitudinal (PET2) glucose metabolism in 38 subjects older than 55 years ranging from normal cognition, cognitive impairment without dementia, and dementia. Design: Cross-sectional regression analyses across subjects. Setting: Multicenter, university-based study of subcortical vascular dementia. Main Outcome Measures: Regional cerebral glucose metabolism was the primary outcome, with the major hypotheses that memory and hippocampal volume are related to temporoparietal hypometabolism while executive function and white matter hyperintensities correlate with frontal lobe hypometabolism. Results: Low baseline hippocampal volume predicted longitudinal development (PET2) of medial temporal hypometabolism. Lower memory was associated with parietal and cingulate hypometabolism at PET1, which increased at the 2-year-follow-up (PET2). Executive function was associated with frontal and temporoparietal hypometabolism at PET1 but only with frontal hypometabolism at follow-up. White matter hyperintensities predicted hypometabolism over time in the frontoparietal regions, predicting a rate of metabolic change (PET1-PET2/time). Conclusions: Low baseline episodic memory and hippocampal volume predict the metabolic alterations associated with Alzheimer disease, whereas elevated baseline white matter hyperintensities predict a different pattern of metabolic decline that is plausibly associated with cerebrovascular disease.
引用
收藏
页码:650 / 655
页数:6
相关论文
共 50 条
  • [1] Cerebrovascular reactivity and cognitive decline in patients with Alzheimer disease
    Silvestrini, M
    Pasqualetti, P
    Baruffaldi, R
    Bartolini, M
    Handouk, Y
    Matteis, M
    Moffa, F
    Provinciali, L
    Vernieri, F
    [J]. STROKE, 2006, 37 (04) : 1010 - 1015
  • [2] Cerebrovascular disease, Alzheimer's disease biomarkers and longitudinal cognitive decline
    Yates, P. A.
    Villemagne, V. L.
    Ames, D.
    Masters, C. L.
    Martins, R. N.
    Desmond, P.
    Burnham, S.
    Maruff, P.
    Ellis, K. A.
    Rowe, C. C.
    [J]. AUSTRALASIAN JOURNAL ON AGEING, 2016, 35 : 18 - 19
  • [3] Distinct pathways for cognitive decline in the presence of Alzheimer's disease pathology or cerebrovascular disease
    Cohen, Ann D.
    [J]. BRAIN, 2016, 139 : 2340 - 2341
  • [4] Subclinical Cerebrovascular Disease and Cognitive Decline
    Hadjiev, Dimiter Ivanov
    Mineva, Petya Pencheva
    [J]. STROKE, 2010, 41 (02) : E112 - E112
  • [5] Galantamine in the treatment of cognitive decline in patients with vascular dementia or Alzheimer's disease with cerebrovascular disease
    Small, G
    Erkinjuntti, T
    Kurz, A
    Lilienfeld, S
    [J]. CNS DRUGS, 2003, 17 (12) : 905 - 914
  • [6] Trajectories of Cognitive Decline in Brain Donors With Autopsy-Confirmed Alzheimer Disease and Cerebrovascular Disease
    Frank, Brandon
    Ally, Madeline
    Tripodis, Yorghos
    Puzo, Christian
    Labriolo, Caroline
    Hurley, Landon
    Martin, Brett
    Palmisano, Joseph
    Chan, Lawrence
    Steinberg, Eric
    Turk, Katherine
    Budson, Andrew
    O'Connor, Maureen
    Au, Rhoda
    Qiu, Wei Qiao
    Goldstein, Lee
    Kukull, Walter
    Kowall, Neil
    Killiany, Ronald
    Stern, Robert
    Stein, Thor
    McKee, Ann
    Mez, Jesse
    Alosco, Michael
    [J]. NEUROLOGY, 2022, 98 (24) : E2454 - E2464
  • [7] Galantamine in the Treatment of Cognitive Decline in Patients with Vascular Dementia or Alzheimer’s Disease with Cerebrovascular Disease
    Gary Small
    Timo Erkinjuntti
    Alexander Kurz
    Sean Lilienfeld
    [J]. CNS Drugs, 2003, 17 : 905 - 914
  • [8] Small concomitant cerebrovascular lesions are not important for cognitive decline in severe Alzheimer disease
    Jellinger, KA
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (03) : 520 - 521
  • [9] Biomarkers of Alzheimer's Disease and Cerebrovascular Disease in Relation to Depressive Symptomatology in Individuals With Subjective Cognitive Decline
    Zapater-Fajari, Mariola
    Diaz-Galvan, Patricia
    Cedres, Nira
    Sterner, Therese Rydberg
    Ryden, Lina
    Sacuiu, Simona
    Waern, Margda
    Zettergren, Anna
    Zetterberg, Henrik
    Blennow, Kaj
    Kern, Silke
    Hidalgo, Vanesa
    Salvador, Alicia
    Westman, Eric
    Skoog, Ingmar
    Ferreira, Daniel
    [J]. JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES, 2024, 79 (02):
  • [10] Epidemiology of cerebrovascular disease related cognitive decline
    Qiu, CX
    Fratiglioni, L
    [J]. INTERNATIONAL PSYCHOGERIATRICS, 2003, 15 : 105 - 110